As a Core Member of CARE-ADD, Dr. Aruna spearheads the Genetics team and started molecular studies trying to understand underpinnings of Autism spectrum in children and aims to nominate molecular pathways for further interrogation and thus to link biological mechanisms with behaviour. At CARE-ADD, Dr. Aruna would also like to establish a large resource of clinical specimens from patients as well as parents to provide material for genetic research studies. The ongoing Biobank will comply with national and international guidelines and will be unique in having a pan India representation. She hopes that understanding the molecular underpinnings that lead to development of ASD diseases may help to devise methods for early detection which will help the patients come into mainstream at the earliest.
Rajarajan Savitha, Korlimarla Aruna, Alexander Annie, Anupama C. E., Ramesh Rakesh, Srinath B. S., Sridhar T. S., Prabhu Jyothi S. Pre-Menopausal Women WithBreast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes; Frontiers in Endocrinology 12, 2021;716
Naik MA, Korlimarla A, Shetty ST, Fernandes AM, Pai SA. Cystic Neutrophilic Granulomatous Mastitis: A Clinicopathological Study With 16s rRNA Sequencing for the Detection of Corynebacteria in Formalin-Fixed Paraffin-Embedded Tissue MD. 2019 Dec; International Journal of Surgical Pathology, https://doi.org/10.1177/1066896919896021
Epigenetic regulation of ER through miR-18a shows ECM activation and identifies poor prognostic subtype within ER+ve HER2-ve breast cancer, Cancer Res. 2019 February 15; (79) (4 Supplement) P6-05-05; DOI: 10.1158/1538-7445.SABCS18-P6-05-05
Dissecting Immune and Molecular Heterogeneity in Indian Triple-Negative Breast Cancer—A population with a higher percentage of Triple-negative breast cancer, Breast Cancer Res Treat (2018). doi.org/10.1007/s10549-017-4585-x
Awarded the ICMR Young Scientist award – 2018, Presented at TCGA Legacy: Multi-omics study of Cancer, Washington DC, USA
An investigation into the mutational spectrum and sub-types of TNBCs in Indians compared to TCGA; A population with high proportion of TNBCs, Oct 2018.
An approach to the identification of tumors driven by HER2 using the integrated activity of oncomiR miR-21 along with HER2 enriched genes. Cancer Res 2013 December 15; 73: P4- 07-09; doi:10.1158/0008-5472.SABCS13-P4-07-09
Alternate epigenetic mechanism for the repression of BRCA1 in sporadic breast cancers mediated by miR182. Ann Oncol. 2014 May; 25 Suppl1: i9. doi: 10.1093/annonc/mdu066.4.PMID: 24764437
A 11 gene q-PCR assay to sub-stratify breast tumors into categories useful in deciding anti- HER-2 therapies. Ann Oncol (2013) 24 (suppl 3): iii26-iii27 doi:10.1093/annonc/mdt083.7
Identification of BRCAness in sporadic breast cancers using a model that integrates multiple assays. Ann Oncol (2013) 24 (suppl 3):
Principal Investigator, Newton Fund Project granted by Institute of Cancer Research, UK, " How do the molecular landscapes of triple-negative breast cancers differ between Indian and Western populations?”. Co-PI- Dr Anguraj Sadanandam, ICR, UK
Principal Investigator, Understanding Clinico-pathological and Molecular profiles of Indian colorectal cancer with respect to advanced disease and treatment challenges as compared to the West – A prospective analysis by building a Biobank - Granted by Global Challenges Research Funding; in collaboration with Institute of Cancer Research, UK, Co-PI- Dr Anguraj Sadanandam, ICR, UK
Co-Principal Investigator, “A retrospective pilot study of analysis of Breast tumors from Lymph node metastasis for evaluation of metastatic potential to distant organ compared to matched primary breast cancer” funded by RGUHS, Year 2017, PI Dr Gnanapriya Sivakumar.
Scientist, Development of an Atlas of Molecular alterations in Breast Cancers in Indian women., Lts.2010-2015, Philanthropic fund by Nadathur Estates Pvt Ltd.
Dr. Aruna is passionate about working to bring Precision medicine closer to clinical practice. To this end, during the course of research, developed molecular diagnostic tests in Breast cancer that not only tease out the innate biology but also identify patients to different available therapies. These tests have been developed